Non-catechol aporphine compound as well as pharmaceutic composition and application thereof

Abstract

The invention relates to a non-catechol aporphine compound as well as a pharmaceutic composition and application thereof, in particular to a non-catechol aporphine compound shown as a general formula (I) or a stereoisomer thereof, a pharmaceutically acceptable salt or a pharmaceutically acceptable solvate and medical application thereof. The compound can be used for preventing or treating diseases related with serotonin 1A receptors, comprising central nervous system diseases, particularly schizophrenia, depressions and dyskinesia caused by medicaments for resisting parkinson's diseases. The invention also relates to the medical composition containing the compound.

Description

technical field The present invention relates to non-catechol aporphine compounds, which have higher activity on serotonin 1A receptors, and therefore can be used in various therapeutic fields, especially in the treatment of diseases of the central nervous system, such as schizophrenia, Depression and movement disorders caused by anti-Parkinson's disease drugs, etc. The present invention also relates to pharmaceutical compositions comprising the compounds described above. Background technique 1. Five serotonin 1A receptors Five serotonin (5-HT) is an important central neurotransmitter. The synthesis, storage, membrane uptake and metabolism of 5-HT together with the 5-HT receptor constitute the 5-HT nervous system. Currently, at least seven types of 5-HT receptors have been cloned, namely 5-HT 1 ~5-HT 7 . Some have several subtypes. Drugs acting on the 5-HT system are used to treat various mental diseases such as schizophrenia and depression, obesity, and sexual dysfu...

AI Technical Summary

Problems solved by technology

Moreover, after chronic medication, many PD patients (40% to 60%) have adverse reactions such as severe involuntary movement or dyskinesia. The patient shows involuntary movement, w

Images